

## Z-DNA, an active element in the genome

Guliang Wang, Karen M. Vasquez

Department of Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park-Research Division, 1808 Park Road 1-C, Smithville, TX 78957

### TABLE OF CONTENTS

1. Abstract
2. Introduction: left-handed Z-DNA conformation
3. Biological activities that facilitate Z-DNA formation
4. Z-DNA-binding proteins
  - 4.1. Double-stranded RNA adenosine deaminase 1, ADAR1
  - 4.2. Vaccinia virus (VV) E3L protein
  - 4.3. DLM-1
5. Z-DNA and human disease
  - 5.1. Z-DNA and chromosomal translocation breakpoints in blood cancers
  - 5.2. Z-DNA and other non-malignant diseases
6. Z-DNA and transcription - cause and effect
  - 6.1. Transcription and induction of the Z-DNA conformation
  - 6.2. Z-DNA and regulation of transcriptional activity
    - 6.2.1. Z-DNA and chromosomal remodeling in transcription regulation
    - 6.2.2. Z-DNA; local and global supercoiling levels in transcription regulation
    - 6.2.3. Transcription machinery stalling at Z-DNA structures
    - 6.2.4. Z-DNA protein binding in transcription regulation
7. Z-DNA-induced genetic instability
  - 7.1. Z-DNA-induced deletion of repeat units in bacteria
  - 7.2. Genetic recombination and Z-DNA-induced genetic instability
  - 7.3. Z-DNA and DNA double-strand breaks in mammalian cells
  - 7.4. Accumulation of DNA damage in the Z-conformation
8. Methods to modulate Z-DNA conformation in vivo
9. Conclusion
10. Acknowledgements
11. References

## 1. ABSTRACT

Z-DNA is a left-handed helical form of DNA in which the double helix winds to the left in a zigzag pattern. DNA containing alternating purine and pyrimidine repeat tracts have the potential to adopt this non-B structure *in vivo* under physiological conditions, particularly in actively transcribed regions of the genome. Z-DNA is thought to play a role in the regulation of gene expression; Z-DNA is also thought to be involved in DNA processing events and/or genetic instability. For example, Z-DNA-forming sequences have the potential to enhance the frequencies of recombination, deletion, and translocation events in cellular systems. Although the biological function(s) of Z-DNA and related Z-DNA-binding proteins are not fully understood, accumulating experimental and clinical evidence support the idea that this non-B DNA conformation is involved in several important biological processes and may provide a target for the prevention and treatment of some human diseases. In this review, we discuss the properties of Z-DNA, proteins that are known to bind specifically to Z-DNA, and potential biological functions of this non-canonical DNA structure.

## 2. INTRODUCTION: LEFT-HANDED Z-DNA CONFORMATION

DNA is capable of adopting many different conformations in addition to the canonical Watson-Crick B-DNA. To date, at least 10 different types of non-B DNA conformations have been identified, and it is likely that other non-B conformations will be discovered.

Z-DNA is a left-handed double helix named after its zigzag arrangement of the sugar-phosphate backbone of the DNA molecule, and was first described in the late 1970s (1). In fact, the first single-crystal X-ray structure of a DNA duplex exhibited a left-handed structure. In a Z-DNA structure, the purines are inverted and in the *syn* conformation, while the pyrimidines remain in the *anti* conformation such that the pyrimidine nucleotide must rotate to maintain the Watson-Crick base-pairing (2). Such an alternating *syn-anti* conformation drives the backbone into a zigzag shape. The major groove essentially disappears in a Z-DNA conformation, while the minor groove remains and maintains its narrow character, corresponding to the B-DNA structure. At the B-Z junction

region, at least one base pair is thought to be disrupted, and the two bases extrude from the DNA duplex on both sides (3). The Z-DNA structure is also more compact relative to B-DNA, with an average of one additional base-pair per turn. How such a significant conformational change from B-DNA to Z-DNA occurs at the atomic level is still a question that remains unanswered. Several models have been proposed to explain the B-to-Z transition [(4), and references therein], including base-pair opening before rotation (1); a series of non-disruptive transfiguration steps for transition (2, 5); an A-type or a stretched intermediate conformation with (4) or without (6) disruption of Watson-Crick base-pairing; and a “zipper” model of sequentially extruding base-pairs from the duplex, permitting their free rotation, consistent with the crystallographic structure of a B-Z DNA junction (3).

Because purines adopt the *syn* conformation more readily than pyrimidines, Z-DNA conformation occurs most readily in alternating purine/pyrimidine d(PuPy) or d(PyPu) repeat sequences, especially alternating guanosine and cytosine residues (7, 8), followed by d(TG)*n* repeats, and d(TA)*n* repeats, though TA repeats tend to adopt a hairpin structure more readily than a Z-DNA structure. GT repeats are the most frequent simple repeating element found in the human genome with estimates of this repeat accounting for more than 0.25% of the total genome (9). Additionally, sequences other than alternating purine-pyrimidine regions, such as d(GGGC)*n*, have also been shown to adopt a Z-DNA conformation (10, 11).

### 3. BIOLOGICAL ACTIVITIES THAT FACILITATE Z-DNA FORMATION *IN VIVO*

Pohl *et al.* (1972) observed that, under high salt conditions (*e.g.*, 4M NaCl), a double-stranded poly d(GC) oligomer underwent a near complete inversion of the ultraviolet circular dichroism spectrum; this inversion was subsequently explained by X-ray diffraction studies that revealed that the oligomer had adopted a Z-DNA conformation (12). Because Z-DNA is a higher energy conformation than B-DNA, the existence of this structure under physiological (low-salt) conditions has been debated. However, it is now recognized that Z-DNA is not limited to formation *in vitro*, as there are numerous lines of evidence demonstrating the existence of Z-DNA structures *in vivo* [for reviews, see (13, 14)].

Z-DNA formation *in vivo* is a dynamic process. DNA sequences adopt a canonical B-form structure the majority of the time with non-B structures occasionally arising as transient intermediates (14). There are a variety of biological or pathological activities that may serve as an impetus for DNA to adopt non-B conformations. For example, when potential Z-DNA-forming sequences are negatively supercoiled, the energy from the torsional stress can convert the B-DNA into a Z-DNA conformation, since each change of a right-hand turn to a left-hand turn would be associated with the removal of 1.8 helical turns of supercoiling. Jaworski *et al.* (1991) showed that the level of Z-DNA formation on a CG repeat was consistent with the level of supercoiling *in vivo*; the Z-DNA conformation was

increased in a topoisomerase I mutant, and was decreased in gyrase mutated *E. coli* strains (15). In addition, Z-DNA was formed at a GT(32) sequence, detected by a Z-DNA antibody, only in a negatively supercoiled plasmid, but not in a relaxed plasmid (16). This finding suggested that Z-DNA could exist *in vivo* under physiological conditions because chromosomal DNA of both eukaryotes and prokaryotes is generally negatively supercoiled. Negative supercoiling can be induced and maintained on a topologically closed region of DNA, *e.g.*, closed circle such as double-stranded viral DNA or plasmid DNA, prokaryotic chromosomal DNA, and segments of long linear molecules of eukaryotic chromosomal DNA bound with proteins on both ends. In eukaryotes, negative supercoiling is generated during the wrapping of DNA around the histones in a left-handed fashion, and positive stress is released by topoisomerases at histone-free DNA regions to ensure DNA is not torsionally strained (17). Unwrapping of the nucleosome releases the energy associated with DNA negative supercoiling that was absorbed during the DNA nucleosomal wrapping process. During transcription, RNA polymerase opens duplex DNA, but does not rotate when moving forward on a DNA template, resulting in tight positive supercoiling in front (released by topoisomerases) and negative supercoiling behind the progressing polymerase. In addition, C<sup>5</sup> methylation at cytosine residues, which is very common in the human genome, can significantly stabilize the Z-DNA conformation under physiological conditions (9). Methylation can increase the helical pitch of DNA (18), lower the free energy of Z-DNA formation, and promote helix unwinding at B-Z junctions (19). A methyl group on cytosine in B-DNA is protruded into the aqueous solvent phase from the major groove of the B-DNA helix and interacts with water molecules, thereby destabilizing the B-DNA structure (20). Although the methyl groups bring only a slight modification in the structure of Z-DNA, they are in close van der Waal's contacts with both the imidazole ring of guanine and the carbon atoms of the sugar, forming a hydrophobic patch on the surface of the molecule to stabilize the Z-DNA conformation (20). When methylated, a linear GC repeat can form Z-DNA with three orders of magnitude less magnesium than required by unmethylated DNA (21). Polyamines such as spermine and spermidine, which are commonly found in eukaryotic cells, also stimulate or stabilize the Z-DNA structure (22-25).

### 4. Z-DNA-BINDING PROTEINS

Because the Z-DNA conformation has been postulated to function as a potential *cis* element, identification of proteins that bind in a structure-specific fashion to Z-DNA could help elucidate the biological role(s) of Z-DNA *in vivo*. In the past decades, a substantial number of Z-DNA-binding proteins have been identified in vaccinia virus (26-29), *Escherichia coli* (30-32), *Saccharomyces cerevisiae* (33), and in *Drosophila* (34, 35), wheat germ (36), zebrafish (37), chicken (38), rat (39), bovine (40), and human cell nuclei (30, 39, 41, 42). Although the functions of most of these Z-DNA-binding proteins have not been completely established, existing evidence suggest that they play important roles in gene

expression, DNA recombination, RNA editing, viral pathogenicity, and tumor development (14). Double-stranded RNA adenosine deaminase 1 (ADAR1), E3L and DLM-1 are among those Z-DNA-binding proteins studied in the most detail and are discussed below. The Z-DNA-binding domain, Z-alpha, from these three proteins demonstrates high sequence similarity, adopting a winged-helix conformation and binding to Z-DNA in a structure-specific manner (43).

### 4.1. Double-stranded RNA adenosine deaminase 1, ADAR1

ADAR1 is member of a deaminase family that edits double-stranded mRNA, and its expression is interferon (IFN) inducible. By converting adenines into inosines, ADAR1 is an important molecule for generating RNA and protein diversity. It has two Z-DNA-binding motifs, Z-alpha and Z-beta. Z-alpha belongs to the family of winged-helix proteins and is able to bind specifically to the left-handed Z-DNA conformation with a  $K_d$  of ~4 nM (44). An interaction between Z-alpha (ADAR1) and supercoiled plasmid DNA with GC(13) or GC(2)CGC(10) inserts was observed by atomic force microscopy (29). Furthermore, Z-alpha (ADAR1) binding was found to induce the B-to-Z transition when the supercoiling level on the plasmids was not at a level to form a Z-DNA structure in the absence of protein (29). Binding of ADAR1 to a Z-DNA structure can remarkably enhance its A-to-I editing efficiency *in vitro* (45). It is proposed that a Z-DNA structure induced by a moving RNA polymerase at an appropriate sequence is able to recruit ADAR1 protein at the transcription site behind the transcription machinery to edit the newly synthesized RNA (44, 46). In addition to RNA editing, a study using a reporter gene under the control of a minimal promoter with a Z-DNA-forming sequence nearby demonstrated that Z-DNA and ADAR1 interaction increased promoter activity (44). When a Z-alpha (ADAR-1) is expressed in the cell, a substantial increase in transcription of the reporter gene was also observed. This result suggests that Z-DNA formation in the promoter region induced or stabilized by a Z-DNA-binding protein, or the Z-alpha (ADAR-1) protein recruited to the promoter itself is involved in transcription regulation (44).

### 4.2. Vaccinia virus (VV) E3L protein

E3L is an IFN resistance gene encoded by vaccinia virus (VV). The N-terminal domain of the E3L protein has sequence similarity to the Z-alpha region found in ADAR1 and DLM-1, but has lower Z-DNA-binding affinity compared with its homologues, due to residue Y48 in the Z-alpha domain that adopts a different side chain conformation which requires rearrangement for binding to Z-DNA (28). Both Z-alpha and C-terminal double-stranded RNA binding domains are required for VV replication in a wide range of host cells (47), and for pathogenesis in a mouse model (48). Vaccinia viruses containing an N-terminal deletion (including the Z-DNA-binding domain) of E3L are attenuated for neuropathogenesis and fail to infect the lungs or brain after intra-nasal installation of C57BL/6 mice. Researchers are considering using the recombinant virus as a vaccine for protecting against smallpox because of decreased neurovirulence (49). VV retains pathogenicity when the E3L Z-DNA-binding

domains are replaced by a similar Z-DNA-binding domain from ADAR1 or DLM-1 (50). Recently, the E3L protein (or the Z-alpha domain alone) was found to increase reporter gene expression in HeLa cells by 5- to 10-fold when the minimal promoter contained IL-6, NF-AT, or p53 elements upstream of the TATA box; it even increased the expression by 2-fold from a basic promoter containing only a TATA box, but showed no effects on a reporter gene either lacking a TATA box or containing a CREB, AP-1, or an NF kappa B element upstream of the TATA box. Further, E3L protein, its Z-alpha domain, or chimeric proteins where the Z-alpha domain was replaced with Z-alpha domain from ADAR1 or DLM-1, significantly protected HeLa cells from hygromycin-B-induced apoptosis in a dose- and time-dependent manner (26). If a deletion or a point mutation was introduced into the Z-alpha region, the protection effect disappeared, indicating that Z-DNA-binding is essential for these activities (26).

### 4.3. DLM-1

DLM-1 is also known as Z-DNA-binding protein 1 (ZBP1). It was identified as a Z-DNA-binding protein by searching sequence databases for homologues of the Z-alpha region of ADAR1 (43). DLM-1 is a tumor associated gene, predominantly expressed in lymphatic tissues and is highly up-regulated in the peritoneal lining of mice bearing mouse ovarian ascites tumor (51). DLM-1 expression is also induced by IFN-gamma or lipopolysaccharide in mouse peritoneal macrophages, so it is speculated to be involved in host responses against cellular stresses, including tumorigenesis and viral infection (51). In addition to the Z-alpha domain, DLM-1 also has a conserved domain homologous to the second Z-DNA-binding domain of ADAR1, Z-beta (39). Both domains are capable of binding Z-DNA, and their binding activities are comparable to that of the Z-alpha domain from ADAR1 (52). Comparison of Z-DNA binding by DLM-1 and ADAR1 reveals a common structure-specific recognition core within the binding domain (43). A potential role of DLM-1, and particularly a role of its Z-DNA binding ability in tumor development and stress response remains unclear.

Z-DNA-binding proteins share common structural characteristics; for example, peptides with alternating lysines (such as KGKGKGK) can bind to Z-DNA specifically (53), and such sequences can be found in many proteins. In many cases, the Z-DNA-binding domains from different proteins can substitute for each other, as discussed above. Further, wild-type E3L protein is a potent inhibitor of ADAR1 deaminase enzymatic activity, probably by competing with the binding site on Z-DNA. Disruption of the Z-DNA-binding domain of E3L by double substitutions of two highly conserved residues abolishes its antagonistic activity (27). These observations provide strong evidence that the interaction of the Z-DNA-binding domain and the Z-DNA structure is crucial for carrying out the biological function of these proteins.

## 5. Z-DNA AND HUMAN DISEASES

### 5.1. Z-DNA and chromosomal translocation breakpoints in blood cancers

A common genetic alteration of blood-cell cancers (leukemia, lymphoma and myeloma) is

chromosomal translocation. Immunoglobulin and T-cell receptor genes are the most frequent receptor loci in related translocations because these genes have active promoters in related blood cells and DNA double-strand breaks (DSBs) are naturally generated in these genes during V(D)J recombination in the production of rearranged active antibody or antigen-receptor genes (54, 55). Interestingly, in many cases breakage hotspots found in related oncogenes have homologies to neither V(D)J sequences nor recombinase recognition sequences, indicating that they are not the result of V(D)J recombination (56). Instead, they often map to regions that are capable of forming Z-DNA or other non-B-DNA structures. The t(12;21)(p13;q22) translocation, fusing the ETV6 and AML1 genes, is the most frequent chromosomal translocation associated with pediatric B-cell precursor acute lymphoblastic leukemia. Several breakpoints and a stable insertion polymorphism are found very near an alternating purine-pyrimidine Z-DNA-forming sequence in the ETV6 gene (57). Boehm *et al.* have examined the breakpoints of three different lymphoid tumor-specific translocations where related genes on both chromosomes are not actively transcribed. In all three translocations studied, a B cell tumor-specific translocation t(11;14)(q13;q32) and two T cell-associated translocations, t(11;14)(p13;q11) and t(7;10)(q35;q24), stretches of alternating purine-pyrimidine residues were found within a short distance of the breakpoint region: an 800 bp Z-DNA-forming sequence was found close to the 11q13 chromosome breakpoint; chromosomal breakage hotspots in four independent tumors with a t(11;14)(p13;q11) translocation contain an adjacent potential Z-DNA region of 62 bp in length at 11p13; and a 32 bp long purine-pyrimidine tract was found at a 10q24 translocation site (58). Foroni *et al.* also reported a similar observation of a Z-DNA-forming sequence at a breakage site on chromosome 10q24 (59). *BCL-2*, *c-MYC* and *SCL* are among those most frequently translocated genes in leukemia, lymphoma, and myeloma; and the recurring breakpoints in these genes have been sequenced in many studies. The t(14;18)(q32;q21) rearrangement juxtaposing the *BCL-2* gene to the immunoglobulin heavy chain gene locus, resulting in constitutive overexpression of *BCL-2* is the hallmark of low-grade non-Hodgkin's lymphomas. Ninety percent of follicular B cell lymphomas carry this translocation (60). The majority of t(14;18) chromosome translocations occur at the 3' region of the *BCL-2* gene where the V(D)J recombination signal sequences were found, indicating the involvement of V(D)J recombinase complex in generating the breaks (61). The 5' breakage hotspot of the *BCL-2* gene (62-68) is the most commonly recurring breakage site in chronic lymphocytic leukemia. Interestingly, multiple Z-DNA-forming elements were found surrounding this common breakpoint and Z-DNA structures were shown to exist *in vivo* using Z-DNA specific antibodies (69, 70). The human *c-MYC* gene is frequently juxtaposed through chromosomal translocation to one of the immunoglobulin loci on chromosomes 2, 14, or 22 (71-73) and the t(8;14)(q24;q32) translocations are found in ~90 % of Burkitt's lymphomas (74). Single-stranded elements in the *c-MYC* gene (75), an indicator for non-B DNA structure conformation, overlap the breakpoint-hotspot at the 5' flanking region near the P1

promoter (76, 77) and the boundary of exon 1 and intron 1 (78). Interestingly, multiple alternating purine-pyrimidine Z-DNA-forming regions have been found near the *c-MYC* P1 promoter and the 3' downstream region (79, 80) near these breakpoints. The *SCL* gene (also known as *TCL5* or *tal-1*) dysregulation can result from joining *SCL* to the *TCRD* or *TCRB* gene in t(1;14) or t(1;7) translocations, and are the most common chromosomal abnormality associated with T-cell acute lymphoblastic leukemia (ALL), found in ~30% of patients with childhood T-cell ALL (81). A translocation breakpoint cluster region and a 90-kb deletion region are found 5' to the coding region of the *SCL* gene. The V(D)J recombinase complex is involved in some *SCL* translocations (82). However, alternating purine and pyrimidine Z-DNA-forming sequences are frequently found in close proximity to the breakpoint when V(D)J recombinase is not involved. In the (1;7) translocation, a 38 bp stretch of alternating GT was found 43 bp 5' of the translocation breakpoint on chromosome region 1p32 (83). In a t(1;3) translocation, a 94 bp tract of alternating purine and pyrimidine sequences were found at the breakpoints on chromosome 3 (82). These findings suggest a close relationship between Z-DNA structures and chromosomal breakage and translocation. Recently, studies from our laboratory showed that both Z-DNA and H-DNA induce DNA DSBs in mammalian cells (84, 85), providing further support for this concept.

### 5.2. Z-DNA and other non-malignant diseases

In addition to chromosomal translocations involved in blood cancers, there is some evidence to suggest that Z-DNA may also play a role in other human diseases. For example, an increased amount of Z-DNA has been identified in DNA from the hippocampus of Alzheimer's patients but not in normal brain DNA, although the role of Z-DNA in disease development has not yet been established (86). The natural resistance associated macrophage protein 1 (*NRAMP1*) gene (also named *SLC11A1*) plays an important role in determining human susceptibility to autoimmune (rheumatoid arthritis, juvenile rheumatoid arthritis, type 1 diabetes, Crohn's disease) and infectious (tuberculosis, leprosy) diseases. A potential Z-DNA-forming sequence in the promoter of the *NRAMP1* gene is involved in its transcriptional regulation, and a polymorphism in this Z-DNA-forming dinucleotide repeat contributes directly to disease susceptibility [(87-89), and references therein]. Z-DNA might also be responsible for metal ion-induced carcinogenesis (90, 91). It was proposed that binding of metal ions, such as nickel ions, might induce and/or stabilize Z-DNA structures (92, 93), and may also react specifically with DNA in the Z conformation resulting in selective base damage which may eventually lead to carcinogenesis (discussed later in this review).

## 6. Z-DNA AND TRANSCRIPTION - CAUSE AND EFFECT

Computer-based programs searching for sequences capable of forming Z-DNA structures reveal a strong bias for their location in transcription initiation sites in 137 human genes studied (94). Thus, many studies have been performed to determine the role of Z-DNA in the regulation of gene expression [(95) and references therein].

A tight correlation between Z-DNA formation and transcriptional activity has been observed (96, 97); transcription can induce Z-DNA conformation and Z-DNA structure can regulate transcription activity.

### 6.1. Transcription and induction of the Z-DNA conformation

Because RNA polymerase does not rotate when moving on a DNA template, transcription results in negative supercoiling behind the polymerase, thus facilitating Z-DNA conformation at permissive regions. Antibodies against Z-DNA bind preferentially to the sites that are actively transcribed (98-100), suggesting that transcription can induce Z-DNA conformation, or the sequences undergoing transcription are unwrapped from the nucleosome and therefore may be more accessible for antibody binding. *In situ* assays in nuclei isolated from *Allium cepa* L. root meristems to detect active RNA polymerases resulted in images that were comparable to those obtained from *in situ* immunodetection of Z-DNA; and inhibitors to RNA polymerase decreased or diminished the Z-DNA staining (101). In permeabilized nuclei from mammalian U937 cells, prepared to ensure the biotin-labeled Z-DNA antibody was able to diffuse into the nuclei while maintaining transcription activity, staining of streptavidin in the nuclei indicated that binding of anti-Z-DNA antibodies was associated with the level of transcription (102). Other examples include experiments demonstrating that three fragments of the *c-MYC* gene near the promoter were found to be bound with Z-DNA antibody only when the *c-MYC* gene was actively transcribed (79, 103).

### 6.2. Z-DNA and regulation of transcriptional activity

Although transcription seems to enhance or stabilize Z-DNA formation, Z-DNA may either enhance or repress transcriptional activity. Fragments containing Z-DNA-forming sequences in the rat nucleolin (*Ncl*) gene, [(CA)(10)(CG)(8)] in the promoter region, and [AC(GC)(5)CCGT(CG)(2)] in the first intron, were isolated and enriched by a Z-DNA antibody in metabolically active permeabilized nuclei; deletion of [(CA)(10)(CG)(8)] in the promoter region increased the promoter activity by ~50% (104). However, alternating purine-pyrimidine tracts have also been shown to result in a strong inhibitory effect to the expression of the tRNA<sup>Pro</sup> gene from *Caenorhabditis elegans* when placed in the flanking regions of the gene or in the promoter (105). Thus, Z-DNA may regulate gene expression *via* different mechanisms, perhaps dependent on its location and stability (see below).

#### 6.2.1. Z-DNA and chromosomal remodeling in transcription regulation

DNA bound to the histone octamer retains the B form and is energetically stabilized by DNA-histone interactions (106). Unwrapping DNA from the nucleosome generates negative supercoiling and can induce Z-DNA structures at permissive sequences. On the other hand, forming a Z-DNA structure can affect nucleosome packaging. In one study, histone octamers were reconstituted on plasmids carrying GC repeats; when plasmids were supercoiled, the CG repeat was much more

susceptible to micrococcal nuclease digestion compared with control B-DNA sequences on supercoiled plasmids. In addition, in relaxed plasmids, the CG repeat was not susceptible to nuclease digestion, suggesting that DNA in the Z form is not efficiently incorporated within core particles, and that a transition from the B to the Z form *in vivo* might result in a significantly altered local placement of nucleosomes (107, 108). The colony-stimulating factor 1 (*CSF1*) gene contains TG repeats in the promoter which are assembled in nucleosomes when *CSF1* is not transcribed. Upon activation of *CSF1* expression, the chromatin-remodeling enzyme BRG1 disrupts this nucleosome, resulting in chromatin remodeling, but not in transcription-initiated Z-DNA formation at the GT repeat in mammalian SW-13 cells (109). Once in the Z form, the promoter region could not be packaged as a nucleosome and was therefore in an open conformation, resulting in increased levels of transcription (109). More recently, a similar result was found in *Saccharomyces cerevisiae*; a CG(9) repeat was found to stimulate gene activity by forming a Z-DNA structure when placed approximately three helical turns (28 bp) or fewer upstream of the *CYC1* TATA box. A nucleosome-scanning assay revealed that the CG(9) repeat sequence in the Z conformation blocks nucleosome formation, producing transcriptionally favorable locations for the TATA box (110).

#### 6.2.2. Z-DNA; local and global supercoiling levels in transcription regulation

It is now well known that promoter activity is regulated by supercoiling levels. RNA polymerase requires transient melting of the DNA duplex at the transcription initiation start site, which can be facilitated by local negative supercoiling stress (111, 112). Negative supercoiling of DNA also facilitates an interaction between transcription factors and DNA, such as transcription factor II D and the fibroin gene promoter, demonstrated in a *in vitro* system using partially purified components from HeLa cells (113). As another example, increasing DNA supercoiling by high osmolarity in growth media resulted in approximately 8-fold higher levels of invasive gene *invA* transcription in *Salmonella typhimurium* than that in lower osmolarity conditions; reducing the level of DNA supercoiling by gyrase inhibitors also reduced expression of *invA* (114). The fibroin gene and adenovirus 2 major late promoter were fully transcribed when templates were supercoiled. Supercoiling can also repress transcription initiation; expression of the histidine biosynthetic operon of *Salmonella typhimurium* is increased by relaxation of supercoiled DNA (115, 116).

A left-handed helical turn of Z-DNA formed at a promoter region can relieve 1.8 helical turns of right-handed negative superhelical twisting (117), therefore Z-DNA can have substantial effects on gene expression rates *via* changing the local DNA conformation. The relative propensities to undergo transition is ordered according to the energies required to drive Z-DNA structure and the energy relieved by the relaxation of supercoiling. For example, a highly negatively supercoiled ( $\Delta LK = -50$ ) *ilvP<sub>G</sub>* promoter has 60- to 70-fold higher activity than its activity on a relaxed template and shifting the supercoiling

level from  $\Delta LK = -12$  to  $-26$  increases promoter activity by five-fold. However, a Z-DNA structure at a promoter region can absorb the supercoiling stress that is required for promoter activation, thereby suppressing the promoter activity (118). A similar effect was demonstrated when Z-DNA was located at a distance from the promoter (119). Increasing the supercoiling level at the *gyrA* (DNA gyrase, subunit A) promoter reduced its activity and a Z-DNA insert actually suppressed the inhibition of supercoiling at the promoter (118). A GT repeat in the *CSF1* promoter, which can form Z-DNA *in vitro*, is required for SWI/SNF-like BAF dependent activation in SW-13 cells. Other Z-DNA-forming sequences can substitute for the GT repeats and maintain the promoter activity, suggesting that it is the structure but not the primary sequence that is required for promoter activity (120). Further, binding of the BAF complex increased the Z-DNA conformation at GT repeats, as indicated by an increased cleavage by a Z-DNA-specific restriction enzyme *in vivo* after BAF binding to the promoter region (120). The authors proposed that the mammalian BAF complex is capable of transiently unwrapping DNA from the nucleosome, resulting in negative supercoiling and a Z-DNA structure at the histone-free GT repeat (109, 120). Moreover, once a Z-DNA structure is adopted, it presents a barrier for the DNA to be re-wrapped into nucleosomes and this region is likely to stay open longer for transcription initiation.

### 6.2.3. Transcription machinery stalling at Z-DNA structures

Since the conformation of left-handed Z-DNA is dramatically different from B-DNA, it's not surprising that templates containing Z-DNA are not ideal for RNA polymerases if not removed by helicases. *E. coli* RNA polymerase (RNAP) was shown to be blocked at the boundary of a negatively supercoiled CG(16) sequence in the Z-DNA conformation *in vitro*, while when that sequence was relaxed and in the B-form, it had no effect on transcription (121). A high error rate for wheat germ RNAPII was observed when CG repeats served as a template (122). We have shown, in collaboration with the Hanawalt group, that shorter transcripts of discrete lengths were obtained in an *in vitro* transcription assay using Z-DNA as a template with T7 RNAP. This result was more pronounced after multiple rounds of transcription, while transcription of the control insert produced full-length transcripts, indicating that the presence of Z-DNA affected the processivity of T7 RNAP (unpublished data).

### 6.2.4. Z-DNA protein binding in transcription regulation


Z-DNA formation can also influence transcriptional activity by interfering with the binding of required transcription factors. If a sequence containing a response element adopted a Z-DNA conformation, then it might not be able to recruit the related transcription factors. For example, when a transcription factor E2F binding site GCGCGAAA has some GC or GT repeats incorporated in an upstream adjacent area, it might adopt a Z-DNA conformation *in vivo* preventing E2F binding. Moreover, Z-DNA-binding proteins (see above) might bind to the target DNA sequence with a higher affinity than the transcription factors, interfering with their binding and/or function (123).

## 7. Z-DNA-INDUCED GENETIC INSTABILITY


Genetic instability is a hallmark of several human diseases including cancer and neurological disorders. There is now substantial evidence indicating that non-B DNA structures can induce genetic instability (124-126). Expansions of triplet repeat elements are known causative factors in the diseases such as Fragile X syndrome, Huntington's, Friedreich's ataxia, and myotonic dystrophy (127, 128). Certain "fragile sites" or "hotspot" regions of the genome that are prone to undergo DNA breaks, translocations, deletions and amplifications (129) are also associated with DNA structure. Zhang and Rowley's review (130) recently summarized the colocalization of *in vivo* topoisomerase II cleavage sites and DNase I hypersensitive sites with genomic breakpoint hotspots in several chromosomal translocations in leukemia. Notably, DNA structure, rather than DNA primary sequence is responsible for both topoisomerase II and DNase I cleavage *in vivo* (131-133). Z-DNA is one of the most frequent sequence elements occurring at the hotspots. DNase I cleaves at the single-stranded DNA region at B-Z junctions, and topoisomerase II prefers to bind and cleave at Z-DNA-forming sequences (134-136), see below.

### 7.1. Z-DNA-induced deletion of repeat units in bacteria

It is well known that plasmids carrying Z-DNA-forming sequences are very difficult to maintain in *E. coli*, suggesting that these structure are unstable in bacteria. When plasmids containing Z-DNA-forming CG repeats, ranging from 6-29 units, are replicated in bacteria, deletions occur at a frequency substantially greater than in plasmids without the CG repeats (137, 138). Freund *et al.* measured the stability of CG repeats in a *lacZ* mutation-reporter plasmid in bacteria using both "*lacZ*+" to "*lacZ*-" and "*lacZ*+" to "*lacZ*+" assays, and found that the Z-DNA-forming CG repeats (ranging from 6-13 units) underwent deletions. For CG(12) and CG(13), ~10% of the total mutants propagated in JM103 cells contained small deletion/insertion events of 1-2 repeat units; the remaining 90% of mutants underwent larger deletions within the repeat sequence. The authors proposed that the small deletions/insertions (of 1-2 units) within the repeats were most likely due to slippage events during replication, based on the following observations: 1) the (GT)<sub>12</sub> and (AT)<sub>12</sub> plasmids showed a similar frequency of 1-2 repeat unit deletions/insertions as CG(12); and 2) the frequency of small deletion/insertion events in a *mutL*-deficient strain was increased ~4-fold compared to the wild-type strain, suggesting that these mutants are product of slippage events left uncorrected due to deficient mismatch repair. However, the larger deletions found within the GC repeats were found to be *mutL* independent. This process appears to be specific to the Z-DNA structure and not to a possible hairpin structure because an AT(12) repeat, which is as susceptible as CG(12) to form a hairpin structure, but does not adopt a Z-DNA conformation, showed a much lower frequency of large deletions compared to the CG(12) repeat sequence (139). It is possible that the Z-DNA structure, particularly when bound and stabilized by proteins, results in DNA polymerase pausing, giving rise to larger or multiple rounds of deletions until the CG repeat is too short to form a stable Z-



**Figure 1.** Z-DNA-induced deletion in bacteria. DNA replication fork pausing at a Z-DNA conformation can result in an increased risk of nascent-template strand disassociation and misalignment. A loop formed in the template strand results in deletion of repeats, while a loop in the nascent strand results in insertion. The same events could occur repeatedly until the CG repeat element is too short to adopt Z-DNA.



**Figure 2.** Possible roles of Z-DNA in recombination. Two molecules form a Holliday junction at the homologous region. If both strands are intact, when the strands wrap around each other to form right-handed B-DNA, a region of similar length on the other end must be in a left-handed conformation. A Z-DNA-forming sequence can greatly facilitate and stabilize this type of Holliday junction (adapted with permission from reference 124).

DNA conformation (Figure 1). Studies from our laboratory provided additional evidence to support this idea: the sequences UY1 (GCGCGCGCGTGTGCGCGCGTGTGCGCGCGC) and RW1009 (CGCGCGCGCGTATATACGCGCGCGC), which contain GT or AT inserts to interrupt the direct CG repeats and reduce the slippage events, showed significantly lower frequencies of small repeat unit deletions in bacteria DH5 alpha, compared with CG(14) repeats (84).

The mechanism of Z-DNA-induced genetic instability is not clear. Although RecA is required for CG repeat-induced intermolecular recombination (to form

dimers or multimers) (137), the deletion events at CG repeats do not require the recombination proteins, RecA or RecBC (137). However, Z-DNA-containing plasmids are much more stable in bacterial SURE® cells (Stratagene) which are defective in genes encoding the nuclease, SbcC, the recombinational proteins, RecB and RecJ, and repair proteins, UmuC and UvrC, indicating that recombination and/or repair activities may be involved in the Z-DNA-induced genetic instability in *E. coli*.

### 7.2. Genetic recombination and Z-DNA-induced genetic instability


A Z-DNA motif GT(30) repeat cloned into a supercoiled plasmid stimulates RecA-independent recombination between GT repeats in bacteria at a much higher frequency than background levels (140). There are numerous studies demonstrating that Z-DNA-forming sequences correlate with recombination hotspots in eukaryotic cells (141, 142). The presence of a 34 bp GT purine-pyrimidine tract was shown to enhance reciprocal meiotic recombination in yeast (143). A hotspot of 1,000 bp in the major histocompatibility complex (MHC) in mice, where several copies of long GT repeats are found, may account for 2% of recombination on the entire chromosome (144, 145). RecA binds to Z-DNA with a faster on rate than to B-DNA, though is not necessary for Z-DNA-induced recombination (146). The difference is a kinetic effect rather than an effect at equilibrium; it binds to both Z- and B-DNA with a stoichiometry of 1 monomer/4 base pairs (146). However, other studies suggest that the high affinity binding of RecA to GC repeats can be attributed to the sequence rather than the structure (32, 147). Proteins purified from human tumor cells using Z-DNA affinity chromatography have an activity to catalyze a recombination strand-transfer reaction similar to that of the RecA and RecI proteins (148).

Topologically, when an intact single-stranded DNA molecule binds to its intact homologous strand and folds into a right-handed helix during homology recognition, the adjacent region must adopt a left-handed conformation. A Z-DNA-forming sequence can thus facilitate recombination by stabilizing this intermediate. Conditions that impair Z-DNA conformation such as addition of anti-Z-DNA antibodies or alteration of the super-helical density of the DNA inhibits strand pairing, suggesting that transient formation of Z-DNA is required for RecI-mediated pairing of duplex molecules during recombination reactions (149) (Figure 2). Alternatively, the DSBs induced by Z-DNA (discussed below) might also lead to recombination by providing a DSB intermediate. The recombination induced by Z-DNA is not necessarily restricted to essentially identical loci. An unequal sister chromatid exchange can occur, resulting in genetic instability (150).

### 7.3. Z-DNA and DNA double-strand breaks in mammalian cells

A recent study from our laboratory demonstrated that a CG(14) Z-DNA-forming sequence induces high levels of genetic instability in both bacterial and mammalian cells. In mammalian cells the CG(14) repeats





**Figure 3.** Z-DNA structure-induced genetic instability in mammalian cells. Z-DNA formed *in vivo*, shown in the red box, is recognized and cleaved by as yet undefined enzymes in mammalian cells, resulting in DSBs (chromosomal breakages) surrounding the structure. The hotspots of DSBs induced by a CG(14) repeat in mammalian cells (84) are shown in the schematic diagram. The error-prone repair at DSBs results in large-scale deletions, translocations and rearrangements.

induce DSBs surrounding the Z-DNA structure resulting in large-scale deletions of the entire repeat element and the flanking mutation-reporter gene. The Z-DNA-induced DSBs are dispersed over a 400 bp region, consistent with chromosomal breakpoints in human diseases such as leukemias and lymphomas (151, 152). Moreover, CG(14)-induced small deletions in the repeats require replication, during which misalignment may lead to deletions and/or expansions. Interestingly, the large-scale deletions, which are the predominant event in mammalian cells (~95% of the mutants) but are very rare in bacteria (<5% of the mutants), are replication-independent. Therefore, we postulate that the large-scale deletions induced by CG(14) are likely initiated by repair processing cleavages surrounding the Z-DNA structure (84), see Figure 3.

The enzyme(s) responsible for the recognition and cleavage of Z-DNA in mammalian cells remains unclear. Potential candidates include DNA topoisomerases, which generate transient DNA DSBs during DNA replication. However conditions that increase the frequency of these DNA breaks can trigger mutagenic events or apoptosis in yeast (134). A cluster of strong binding and cleavage sites for DNA topoisomerase II are located near Human Immunodeficiency Virus (HIV) integration sites in the human genome. Interestingly, these sequences consist of a complex repeating element, and Z-DNA motifs (135).

*Drosophila melanogaster* DNA topoisomerase II binds to and relaxes negatively supercoiled DNA containing Z-DNA-forming sequences (136). In addition, purified chicken topoisomerase II has cleavage activity on both DNA strands in a 54 bp alternating purine-pyrimidine region from the human beta-globin gene, which is also a hotspot for recombination and mutation *in vivo*. The activity of this enzyme on alternating purine-pyrimidine sequences appears to be proportional to the length of the repeating sequence (153). These findings suggest a role for DNA topoisomerase II in Z-DNA-induced DSBs and genetic instability.

## 7.4. Accumulation of DNA damage in the Z-conformation

Different types of DNA damaging agents can cause non-random lesions along the DNA. The type of DNA motifs to be preferentially attacked depends upon the chemical or physical nature of the assaulting agent and the DNA base composition and structure. In a normal B-DNA structure, the base-pairing between strands is protected within the helix. However, the guanosine nucleotides are in a *syn* position in a Z-DNA conformation, with the purine base located over the sugar without protection, thus possibly being more accessible to DNA damaging factors (154). The abnormal positioning or absence of nucleosomes can also change the sensitivity of the DNA to genotoxic agents. UV irradiation has been shown to induce significant chromatin fragmentation at repetitive sequences, particularly at GT repeats (a Z-DNA-forming sequence) and long stretches of homopurine/homopyrimidine regions (potential H-DNA-forming sequences) (155). The guanine sites in the Z-DNA structure are more sensitive, and the cytosine sites less sensitive to ionizing radiation, leading to a characteristic signature of the Z-form DNA (156). Hyperreactivity to certain agents has also been observed at the B-Z junction (157). Although guanine N<sup>7</sup> lies on the surface of the major groove in B-DNA, access of Ni<sup>2+</sup> and Co<sup>2+</sup> to guanine is apparently inhibited by the steric constraints. However, the solvent accessibility of guanine N<sup>7</sup> increases greatly upon formation of Z-DNA, therefore Ni<sup>2+</sup> selectively induces oxidative damage on guanine in the Z-DNA, but not in the B-DNA conformation (158). In addition, damage occurring to the DNA in a Z-DNA conformation is likely more resistant to processing by DNA repair enzymes. For example, bases damaged by alkylation such as N<sup>7</sup>-methylguanine and O<sup>6</sup>-methylguanine, are removed by a DNA glycosylase, and O<sup>6</sup>-methylguanine-DNA methyltransferase, respectively, in B-DNA but are not efficiently repaired by these enzymes when present in Z-DNA (159, 160). Thus, it is possible that endogenous (oxidative) DNA damage accumulates at Z-DNA regions contributing to their induction of genetic instability.

## 8. METHODS TO MODULATE Z-DNA CONFORMATION *IN VIVO*

Since the Z-DNA structure plays important roles on DNA metabolic processes *in vivo*, researchers are attempting to find or create small molecules that can interfere with Z-DNA specifically, to either enhance or inhibit the biological functions in which Z-DNA participates.



Transition metal ions are able to promote the Z-DNA conformation at alternating purine and pyrimidine sequences *in vitro* (161, 162). Monovalent alkaline cations drive a B to Z transition in high salt (~2.3 M for Na<sup>+</sup> and 4.7 M for Cs<sup>+</sup>). Mg<sup>2+</sup>, Ca<sup>2+</sup>, and Ba<sup>2+</sup> cations induce Z-DNA structure formation at poly[d(G-C)]. The divalent transition metal ions Zn<sup>2+</sup>, Cu<sup>2+</sup>, Mn<sup>2+</sup>, Co<sup>2+</sup>, and Ni<sup>2+</sup> tend to coordinate to guanosine N<sup>7</sup>, which is more accessible in the Z-DNA than in the B-DNA structure, and drive the B to Z transition at low concentrations [(163), and references therein]. Aluminum, which has been found to be increased in the serum samples of Fragile X syndrome patients (1.8 x 10<sup>-6</sup> M vs. 0.53 x 10<sup>-6</sup> M in unaffected individuals), can induce Z-DNA structure formation at a CCG(12) repeat localized at the 5' end of the non-coding regions of the Fragile X mental retardation-1 (FMR1) gene *in vitro*. Once formed, the structure was quite stable even after the total removal of aluminum from the reaction (164). On the other hand, chloride anions inhibit the Ni<sup>2+</sup> promoted Z-DNA conformation *in vitro* very effectively by modulating the interaction of nickel ions with DNA (165). The anticancer drug (+)-daunorubicin binds selectively to right-handed B-DNA. It can also allosterically convert Z-DNA-forming sequences to a B-DNA form; however, its synthesized enantiomer, (-)-daunorubicin (WP900), binds selectively to left-handed DNA, and can convert B-DNA to a Z-DNA form at sequences with the potential to adopt Z-DNA (166). The naturally occurring polyamines putrescine, spermidine, and spermine can induce Z-DNA structures *in vitro* (23). Drugs that inhibit the production of polyamines have therefore been tested for the treatment of human autoimmune disease where a Z-DNA structure is involved. The survival rate of female MRL-*lpr/lpr* mice was increased by 29% by treatment with Difluoromethylornithine (DFMO), a drug that inactivates ornithine decarboxylase and thus reduces the production of polyamines. This effect was suggested to be the result of the inhibitory action of DFMO on cell proliferation and the prevention of DNA from forming an immunogenic Z-DNA conformation (167).

In addition to molecules that can change DNA structure directly, compounds that bind to the Z-DNA-binding proteins and interfere with DNA-protein interaction might also be useful in modulating Z-DNA-related metabolism. Through structure-based screening of a chemical database, Kim *et al.* (168) discovered small molecules that could bind to a Z-DNA-binding protein and inhibit its interaction with Z-DNA. According to the X-ray crystal structure of Z-alpha domain of human ADAR1 protein bound to Z-DNA hexamer d(CGCGCG)<sub>2</sub>, three non-charged small compounds containing several hydrogen bond acceptor atoms out of a total of 78,425 compounds in a chemical database were found to have the ability to interact with Z-DNA-binding protein and inhibit the interaction of the protein with the Z-DNA, identified by inhibition of Z-DNA-binding in gel-shift assays. Although further work is required to increase the affinity and specificity of these compounds to Z-DNA, such efforts provide the potential of development of a new class of therapeutic agents based on interacting with Z-DNA for the treatment of related human diseases.

## 9. CONCLUSION

The discovery that Z-DNA and other non-B DNA structures are actively involved in many biological and pathological processes has changed our thinking about how the physical structure of genes (DNA) impacts on disease development. The exact functional/mechanistic role(s) of Z-DNA *in vivo* is not yet completely understood (due in part, to experimental difficulties posed by the transient nature of the Z-DNA structure), but certainly substantial evidence exists to support its involvement in these processes. Clearly, additional research is needed to address the developmentally relevant temporal and tissue specific influences of the Z-DNA structure. Identification of the complete set of trans-acting factors that interact with the Z-DNA and their disease relevance is also of paramount importance. Exciting progress is currently being made in several laboratories to discover ways to modulate the conformation of DNA in particular regions of the genome as well as to influence the binding of proteins that interact with non-canonical DNA structures as strategies to prevent or treat human disease.

An insightful commentary on the status of the field has been contributed by Rich and Zhang (14), and is well summarized in this excerpt from their review that the research is still in its infancy and there is still a “long road to biological function”. The potential of exploiting modulation of DNA structure for therapeutic benefit should eventually result in a new field of disease prevention and therapy.

## 10. ACKNOWLEDGEMENTS

We thank Dr. Rick A. Finch for critical review of the manuscript and Sarah Henninger for manuscript preparation. This work was supported by an NCI grant to K.M.V. (CA93729) and an Odyssey Special Fellowship (to G.W.) supported by the Odyssey Program and the Theodore N. Law Award for Scientific Achievement at The University of Texas M.D. Anderson Cancer Center.

## 11. REFERENCES

1. Wang, A. H., G. J. Quigley, F. J. Kolpak, J. L. Crawford, J. H. van Boom, G. van der Marel & A. Rich: Molecular structure of a left-handed double helical DNA fragment at atomic resolution. *Nature*, 282, 680-6 (1979)
2. Harvey, S. C.: DNA structural dynamics: longitudinal breathing as a possible mechanism for the B in equilibrium Z transition. *Nucleic Acids Res*, 11, 4867-78 (1983)
3. Ha, S. C., K. Lowenhaupt, A. Rich, Y. G. Kim & K. K. Kim: Crystal structure of a junction between B-DNA and Z-DNA reveals two extruded bases. *Nature*, 437, 1183-6 (2005)
4. Kastenholz, M. A., T. U. Schwartz & P. H. Hunenberger: The transition between the B and Z conformations of DNA investigated by targeted molecular dynamics simulations with explicit solvation. *Biophys J*, 91, 2976-90 (2006)
5. Chaires, J. B. & J. M. Sturtevant: Thermodynamics of the B to Z transition in poly (dGdC). *Biopolymers*, 27, 1375-87 (1988)

6. Saenger, W. & U. Heinemann: Raison d'etre and structural model for the B-Z transition of poly d (G-C).poly d (G-C). *FEBS Lett*, 257, 223-7 (1989)
7. Malfroy, B., N. Rousseau, N. Vogt, E. Viegas-Pequignot, B. Dutrillaux & M. Leng: Nucleotide sequence of an heterochromatic segment recognized by the antibodies to Z-DNA in fixed metaphase chromosomes. *Nucleic Acids Res*, 14, 3197-214 (1986)
8. Johnston, B. H.: Generation and detection of Z-DNA. *Methods Enzymol*, 211, 127-58 (1992)
9. Lander, E. S., L. M. Linton, B. Birren, C. Nusbaum, M. C. Zody, J. Baldwin, *et al*: Initial sequencing and analysis of the human genome. *Nature*, 409, 860-921 (2001)
10. Feigon, J., A. H. Wang, G. A. van der Marel, J. H. van Boom & A. Rich: Z-DNA forms without an alternating purine-pyrimidine sequence in solution. *Science*, 230, 82-4 (1985)
11. Eichman, B. F., G. P. Schroth, B. E. Basham & P. S. Ho: The intrinsic structure and stability of out-of-alternation base pairs in Z-DNA. *Nucleic Acids Res*, 27, 543-50 (1999)
12. Pohl, F. M. & T. M. Jovin: Salt-induced co-operative conformational change of a synthetic DNA: equilibrium and kinetic studies with poly (dG-dC). *J Mol Biol*, 67, 375-96 (1972)
13. Herbert, A. & A. Rich: The biology of left-handed Z-DNA. *J Biol Chem*, 271, 11595-8 (1996)
14. Rich, A. & S. Zhang: Timeline: Z-DNA: the long road to biological function. *Nat Rev Genet*, 4, 566-72 (2003)
15. Jaworski, A., N. P. Higgins, R. D. Wells & W. Zacharias: Topoisomerase mutants and physiological conditions control supercoiling and Z-DNA formation *in vivo*. *J Biol Chem*, 266, 2576-81 (1991)
16. Nordheim, A. & A. Rich: The sequence (dC-dA)<sub>n</sub> X (dG-dT)<sub>n</sub> forms left-handed Z-DNA in negatively supercoiled plasmids. *Proc Natl Acad Sci U S A*, 80, 1821-5 (1983)
17. Bates, A. D. & A. Maxwell: DNA topology. Oxford University Press, Oxford ; New York (2005)
18. Gruenbaum, Y., H. Cedar & A. Razin: Substrate and sequence specificity of a eukaryotic DNA methylase. *Nature*, 295, 620-2 (1982)
19. Zacharias, W., M. Caserta, T. R. O'Connor, J. E. Larson & R. D. Wells: Cytosine methylation as an effector of right-handed to left-handed DNA structural transitions. *Gene*, 74, 221-4 (1988)
20. Fujii, S., A. H. Wang, G. van der Marel, J. H. van Boom & A. Rich: Molecular structure of (m5 dC-dG)<sub>3</sub>: the role of the methyl group on 5-methyl cytosine in stabilizing Z-DNA. *Nucleic Acids Res*, 10, 7879-92 (1982)
21. Behe, M. & G. Felsenfeld: Effects of methylation on a synthetic polynucleotide: the B--Z transition in poly (dG-m5dC).poly (dG-m5dC). *Proc Natl Acad Sci U S A*, 78, 1619-23 (1981)
22. Juranic, Z., M. Kidric, R. Tomin, I. Juranic, I. Spuzic & J. Petrovic: The importance of the specific Z-DNA structure and polyamines in carcinogenesis: fact or fiction. *Med Hypotheses*, 35, 353-7 (1991)
23. Thomas, T. J., U. B. Gunnia & T. Thomas: Polyamine-induced B-DNA to Z-DNA conformational transition of a plasmid DNA with (dG-dC)<sub>n</sub> insert. *J Biol Chem*, 266, 6137-41 (1991)
24. Thomas, T. J. & T. Thomas: Polyamine-induced Z-DNA conformation in plasmids containing (dA-dC)<sub>n</sub>. (dG-dT)<sub>n</sub> inserts and increased binding of lupus autoantibodies to the Z-DNA form of plasmids. *Biochem J*, 298 ( Pt 2), 485-91 (1994)
25. Howell, M. L., G. P. Schroth & P. S. Ho: Sequence-dependent effects of spermine on the thermodynamics of the B-DNA to Z-DNA transition. *Biochemistry*, 35, 15373-82 (1996)
26. Kwon, J. A. & A. Rich: Biological function of the vaccinia virus Z-DNA-binding protein E3L: gene transactivation and antiapoptotic activity in HeLa cells. *Proc Natl Acad Sci U S A*, 102, 12759-64 (2005)
27. Liu, Y., K. C. Wolff, B. L. Jacobs & C. E. Samuel: Vaccinia virus E3L interferon resistance protein inhibits the interferon-induced adenosine deaminase A-to-I editing activity. *Virology*, 289, 378-87 (2001)
28. Kahmann, J. D., D. A. Wecking, V. Putter, K. Lowenhaupt, Y. G. Kim, P. Schmieder, H. Oschkinat, A. Rich & M. Schade: The solution structure of the N-terminal domain of E3L shows a tyrosine conformation that may explain its reduced affinity to Z-DNA *in vitro*. *Proc Natl Acad Sci U S A*, 101, 2712-7 (2004)
29. Kim, Y. G., K. Lowenhaupt, D. B. Oh, K. K. Kim & A. Rich: Evidence that vaccinia virulence factor E3L binds to Z-DNA *in vivo*: Implications for development of a therapy for poxvirus infection. *Proc Natl Acad Sci U S A*, 101, 1514-8 (2004)
30. Krishna, P., B. P. Kennedy, D. M. Waisman, J. H. van de Sande & J. D. McGhee: Are many Z-DNA binding proteins actually phospholipid-binding proteins? *Proc Natl Acad Sci U S A*, 87, 1292-5 (1990)
31. Lafer, E. M., R. J. Sousa & A. Rich: Z-DNA-binding proteins in Escherichia coli purification, generation of monoclonal antibodies and gene isolation. *J Mol Biol*, 203, 511-6 (1988)
32. Blaho, J. A. & R. D. Wells: Left-handed Z-DNA binding by the recA protein of Escherichia coli. *J Biol Chem*, 262, 6082-8 (1987)
33. Zhang, S., C. Lockshin, A. Herbert, E. Winter & A. Rich: Zuoitin, a putative Z-DNA binding protein in Saccharomyces cerevisiae. *Embo J*, 11, 3787-96 (1992)
34. Nordheim, A., P. Tesser, F. Azorin, Y. H. Kwon, A. Moller & A. Rich: Isolation of Drosophila proteins that bind selectively to left-handed Z-DNA. *Proc Natl Acad Sci U S A*, 79, 7729-33 (1982)
35. Arndt-Jovin, D. J., A. Udvardy, M. M. Garner, S. Ritter & T. M. Jovin: Z-DNA binding and inhibition by GTP of Drosophila topoisomerase II. *Biochemistry*, 32, 4862-72 (1993)
36. Lafer, E. M., R. Sousa, B. Rosen, A. Hsu & A. Rich: Isolation and characterization of Z-DNA binding proteins from wheat germ. *Biochemistry*, 24, 5070-6 (1985)
37. Rothenburg, S., N. Deigendesch, K. Dittmar, F. Koch-Nolte, F. Haag, K. Lowenhaupt & A. Rich: A PKR-like eukaryotic initiation factor 2alpha kinase from zebrafish contains Z-DNA binding domains instead of dsRNA binding domains. *Proc Natl Acad Sci U S A*, 102, 1602-7 (2005)
38. Herbert, A. G., J. R. Spitzner, K. Lowenhaupt & A. Rich: Z-DNA binding protein from chicken blood nuclei. *Proc Natl Acad Sci U S A*, 90, 3339-42 (1993)

39. Rothenburg, S., T. Schwartz, F. Koch-Nolte & F. Haag: Complex regulation of the human gene for the Z-DNA binding protein DLM-1. *Nucleic Acids Res*, 30, 993-1000 (2002)
40. Rohner, K. J., R. Hobi & C. C. Kuenzle: Z-DNA-binding proteins. Identification critically depends on the proper choice of ligands. *J Biol Chem*, 265, 19112-5 (1990)
41. Leith, I. R., R. T. Hay & W. C. Russell: Detection of Z DNA binding proteins in tissue culture cells. *Nucleic Acids Res*, 16, 8277-89 (1988)
42. Pham, H. T., M. Y. Park, K. K. Kim, Y. G. Kim & J. H. Ahn: Intracellular localization of human ZBP1: Differential regulation by the Z-DNA binding domain, Zalpha, in splice variants. *Biochem Biophys Res Commun*, 348, 145-52 (2006)
43. Schwartz, T., J. Behlke, K. Lowenhaupt, U. Heinemann & A. Rich: Structure of the DLM-1-Z-DNA complex reveals a conserved family of Z-DNA-binding proteins. *Nat Struct Biol*, 8, 761-5 (2001)
44. Oh, D. B., Y. G. Kim & A. Rich: Z-DNA-binding proteins can act as potent effectors of gene expression *in vivo*. *Proc Natl Acad Sci U S A*, 99, 16666-71 (2002)
45. Koeris, M., L. Funke, J. Shrestha, A. Rich & S. Maas: Modulation of ADAR1 editing activity by Z-RNA *in vitro*. *Nucleic Acids Res*, 33, 5362-70 (2005)
46. Herbert, A. & A. Rich: Left-handed Z-DNA: structure and function. *Genetica*, 106, 37-47 (1999)
47. Beattie, E., E. B. Kauffman, H. Martinez, M. E. Perkus, B. L. Jacobs, E. Paoletti & J. Tartaglia: Host-range restriction of vaccinia virus E3L-specific deletion mutants. *Virus Genes*, 12, 89-94 (1996)
48. Brandt, T. A. & B. L. Jacobs: Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. *J Virol*, 75, 850-6 (2001)
49. Brandt, T., M. C. Heck, S. Vijaysri, G. M. Jentarra, J. M. Cameron & B. L. Jacobs: The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response. *Virology*, 333, 263-70 (2005)
50. Hauns, K. Lowenhaupt, B. L. Jacobs & A. Rich: A role for Kim, Y. G., M. Muralinath, T. Brandt, M. Percy, K. Z-DNA binding in vaccinia virus pathogenesis. *Proc Natl Acad Sci U S A*, 100, 6974-9 (2003)
51. Fu, Y., N. Comella, K. Tognazzi, L. F. Brown, H. F. Dvorak & O. Kocher: Cloning of DLM-1, a novel gene that is up-regulated in activated macrophages, using RNA differential display. *Gene*, 240, 157-63 (1999)
52. Ha, S. C., D. Van Quyen, H. Y. Hwang, D. B. Oh, B. A. Brown, 2nd, S. M. Lee, H. J. Park, J. H. Ahn, K. K. Kim & Y. G. Kim: Biochemical characterization and preliminary X-ray crystallographic study of the domains of human ZBP1 bound to left-handed Z-DNA. *Biochim Biophys Acta*, 1764, 320-3 (2006)
53. Kim, Y. G., H. J. Park, K. K. Kim, K. Lowenhaupt & A. Rich: A peptide with alternating lysines can act as a highly specific Z-DNA binding domain. *Nucleic Acids Res*, 34, 4937-42 (2006)
54. Gellert, M.: Recent advances in understanding V (D)J recombination. *Adv Immunol*, 64, 39-64 (1997)
55. Sadofsky, M. J.: The RAG proteins in V (D)J recombination: more than just a nuclease. *Nucleic Acids Res*, 29, 1399-409 (2001)
56. Hecht, J. L. & J. C. Aster: Molecular biology of Burkitt's lymphoma. *J Clin Oncol*, 18, 3707-21 (2000)
57. Thandla, S. P., J. E. Ploski, S. Z. Raza-Egilmez, P. P. Chhalliyil, A. W. Block, P. J. de Jong & P. D. Aplan: ETV6-AML1 translocation breakpoints cluster near a purine/pyrimidine repeat region in the ETV6 gene. *Blood*, 93, 293-9 (1999)
58. Boehm, T., L. Mengle-Gaw, U. R. Kees, N. Spurr, I. Lavenir, A. Forster & T. H. Rabbitts: Alternating purine-pyrimidine tracts may promote chromosomal translocations seen in a variety of human lymphoid tumours. *Embo J*, 8, 2621-31 (1989)
59. Foroni, L., T. Boehm, F. Lampert, Y. Kaneko, S. Raimondi & T. H. Rabbitts: Multiple methylation-free islands flank a small breakpoint cluster region on 11p13 in the t (11;14) (p13;q11) translocation. *Genes Chromosomes Cancer*, 1, 301-9 (1990)
60. Yunis, J. J., G. Frizzera, M. M. Oken, J. McKenna, A. Theologides & M. Arnesen: Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. *N Engl J Med*, 316, 79-84 (1987)
61. Vaandrager, J. W., E. Schuurin, K. Philippo & P. M. Kluin: V (D)J recombinase-mediated transposition of the BCL2 gene to the IGH locus in follicular lymphoma. *Blood*, 96, 1947-52 (2000)
62. Yabumoto, K., T. Akasaka, M. Muramatsu, N. Kadowaki, T. Hayashi, H. Ohno, S. Fukuhara & M. Okuma: Rearrangement of the 5' cluster region of the BCL2 gene in lymphoid neoplasm: a summary of nine cases. *Leukemia*, 10, 970-7 (1996)
63. Tashiro, S., M. Takechi, H. Asou, K. Takauchi, T. Kyo, H. Dohy, M. Kikuchi, N. Kamada & Y. Tsujimoto: Cytogenetic 2; 18 and 18; 22 translocation in chronic lymphocytic leukemia with juxtaposition of bcl-2 and immunoglobulin light chain genes. *Oncogene*, 7, 573-7 (1992)
64. Hillion, J., C. Mecucci, A. Avenin, D. Leroux, I. Wlodarska, H. Van Den Berghe & C. J. Larsen: A variant translocation t (2;18) in follicular lymphoma involves the 5' end of bcl-2 and Ig kappa light chain gene. *Oncogene*, 6, 169-72 (1991)
65. Adachi, M., J. Cossman, D. Longo, C. M. Croce & Y. Tsujimoto: Variant translocation of the bcl-2 gene to immunoglobulin lambda light chain gene in chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A*, 86, 2771-4 (1989)
66. Yonetani, N., C. Ueda, T. Akasaka, M. Nishikori, T. Uchiyama & H. Ohno: Heterogeneous breakpoints on the immunoglobulin genes are involved in fusion with the 5' region of BCL2 in B-cell tumors. *Jpn J Cancer Res*, 92, 933-40 (2001)
67. Akasaka, T., H. Akasaka, N. Yonetani, H. Ohno, H. Yamabe, S. Fukuhara & M. Okuma: Refinement of the BCL2/immunoglobulin heavy chain fusion gene in t (14;18) (q32;q21) by polymerase chain reaction amplification for long targets. *Genes Chromosomes Cancer*, 21, 17-29 (1998)
68. Adachi, M., A. Tefferi, P. R. Greipp, T. J. Kipps & Y. Tsujimoto: Preferential linkage of bcl-2 to immunoglobulin

- light chain gene in chronic lymphocytic leukemia. *J Exp Med*, 171, 559-64 (1990)
69. Adachi, M. & Y. Tsujimoto: Potential Z-DNA elements surround the breakpoints of chromosome translocation within the 5' flanking region of bcl-2 gene. *Oncogene*, 5, 1653-7 (1990)
70. Seite, P., D. Leroux, J. Hillion, M. Monteil, R. Berger, D. Mathieu-Mahul & C. J. Larsen: Molecular analysis of a variant 18;22 translocation in a case of lymphocytic lymphoma. *Genes Chromosomes Cancer*, 6, 39-44 (1993)
71. Wiener, F., S. Ohno, M. Babonits, J. Sumegi, Z. Wirschubsky, G. Klein, J. F. Mushinski & M. Potter: Hemizygous interstitial deletion of chromosome 15 (band D) in three translocation-negative murine plasmacytomas. *Proc Natl Acad Sci U S A*, 81, 1159-63 (1984)
72. Akasaka, T., H. Akasaka, C. Ueda, N. Yonetani, Y. Maesako, A. Shimizu, H. Yamabe, S. Fukuhara, T. Uchiyama & H. Ohno: Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. *J Clin Oncol*, 18, 510-18 (2000)
73. Kovalchuk, A. L., J. R. Muller & S. Janz: Deletional remodeling of c-myc-deregulating chromosomal translocations. *Oncogene*, 15, 2369-77 (1997)
74. Rabbitts, T. H. & T. Boehm: Structural and functional chimerism results from chromosomal translocation in lymphoid tumors. *Adv Immunol*, 50, 119-46 (1991)
75. Michelotti, G. A., E. F. Michelotti, A. Pullner, R. C. Duncan, D. Eick & D. Levens: Multiple single-stranded cis elements are associated with activated chromatin of the human c-myc gene *in vivo*. *Mol Cell Biol*, 16, 2656-69 (1996)
76. Saglio, G., M. Grazia Borrello, A. Guerrasio, G. Sozzi, A. Serra, P. F. di Celle, R. Foa, M. Ferrarini, S. Roncella, C. Borgna Pignatti & *et al.*: Preferential clustering of chromosomal breakpoints in Burkitt's lymphomas and L3 type acute lymphoblastic leukemias with a t (8;14) translocation. *Genes Chromosomes Cancer*, 8, 1-7 (1993)
77. Care, A., L. Cianetti, A. Giampaolo, N. M. Sposi, V. Zappavigna, F. Mavilio, G. Alimena, S. Amadori, F. Mandelli & C. Peschle: Translocation of c-myc into the immunoglobulin heavy-chain locus in human acute B-cell leukemia. A molecular analysis. *Embo J*, 5, 905-11 (1986)
78. Wilda, M., K. Busch, I. Klose, T. Keller, W. Woessmann, J. Kreuder, J. Harbott & A. Borkhardt: Level of MYC overexpression in pediatric Burkitt's lymphoma is strongly dependent on genomic breakpoint location within the MYC locus. *Genes Chromosomes Cancer*, 41, 178-82 (2004)
79. Wolfl, S., B. Wittig & A. Rich: Identification of transcriptionally induced Z-DNA segments in the human c-myc gene. *Biochim Biophys Acta*, 1264, 294-302 (1995)
80. Rimokh, R., J. P. Rouault, K. Wahbi, M. Gadoux, M. Lafage, E. Archimbaud, C. Charrin, O. Gentilhomme, D. Germain, J. Samarut & *et al.*: A chromosome 12 coding region is juxtaposed to the MYC protooncogene locus in a t (8;12) (q24;q22) translocation in a case of B-cell chronic lymphocytic leukemia. *Genes Chromosomes Cancer*, 3, 24-36 (1991)
81. Xia, Y., L. Brown, J. T. Tsan, C. Y. Yang, M. J. Siciliano, W. M. Crist, A. J. Carroll & R. Baer: The translocation (1;14) (p34;q11) in human T-cell leukemia: chromosome breakage 25 kilobase pairs downstream of the TAL1 protooncogene. *Genes Chromosomes Cancer*, 4, 211-6 (1992)
82. Aplan, P. D., S. C. Raimondi & I. R. Kirsch: Disruption of the SCL gene by a t (1;3) translocation in a patient with T cell acute lymphoblastic leukemia. *J Exp Med*, 176, 1303-10 (1992)
83. Fitzgerald, T. J., G. A. Neale, S. C. Raimondi & R. M. Goorha: c-tal, a helix-loop-helix protein, is juxtaposed to the T-cell receptor-beta chain gene by a reciprocal chromosomal translocation: t (1;7) (p32;q35). *Blood*, 78, 2686-95 (1991)
84. Wang, G., L. A. Christensen & K. M. Vasquez: Z-DNA-forming sequences generate large-scale deletions in mammalian cells. *Proc Natl Acad Sci U S A*, 103, 2677-82 (2006)
85. Wang, G. & K. M. Vasquez: Naturally occurring H-DNA-forming sequences are mutagenic in mammalian cells. *Proc Natl Acad Sci U S A*, 101, 13448-13453 (2004)
86. Suram, A., K. S. Rao, K. S. Latha & M. A. Viswamitra: First evidence to show the topological change of DNA from B-DNA to Z-DNA conformation in the hippocampus of Alzheimer's brain. *Neuromolecular Med*, 2, 289-97 (2002)
87. Blackwell, J. M. & S. Searle: Genetic regulation of macrophage activation: understanding the function of Nramp1 (=Ity/Lsh/Bcg). *Immunol Lett*, 65, 73-80 (1999)
88. Takahashi, K., J. Satoh, Y. Kojima, K. Negoro, M. Hirai, Y. Hinokio, Y. Kinouchi, S. Suzuki, N. Matsuura, T. Shimosegawa & Y. Oka: Promoter polymorphism of SLC11A1 (formerly NRAMP1) confers susceptibility to autoimmune type 1 diabetes mellitus in Japanese. *Tissue Antigens*, 63, 231-6 (2004)
89. Searle, S. & J. M. Blackwell: Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility. *J Med Genet*, 36, 295-9 (1999)
90. Sunderman, F. W., Jr.: Mechanisms of nickel carcinogenesis. *Scand J Work Environ Health*, 15, 1-12 (1989)
91. Sunderman, F. W., Jr.: Recent advances in metal carcinogenesis. *Ann Clin Lab Sci*, 14, 93-122 (1984)
92. Liquier, J., P. Bourtayre, L. Pizzorni, F. Sournies, J. F. Labarre & E. Taillandier: Spectroscopic studies of conformational transitions in double stranded DNAs in the presence of carcinogenic nickel compounds and an antitumoral drug (SOAZ). *Anticancer Res*, 4, 41-4 (1984)
93. Taillandier, E., J. A. Taboury, S. Adam & J. Liquier: Left-handed helical structure of poly[d (A-C)].poly[d (G-T)] studied by infrared spectroscopy. *Biochemistry*, 23, 5703-6 (1984)
94. Schroth, G. P., P. J. Chou & P. S. Ho: Mapping Z-DNA in the human genome. Computer-aided mapping reveals a nonrandom distribution of potential Z-DNA-forming sequences in human genes. *J Biol Chem*, 267, 11846-55 (1992)
95. Sinden, R. R.: DNA structure and function. Academic Press, San Diego (1994)
96. Wolfl, S., C. Martinez, A. Rich & J. A. Majzoub: Transcription of the human corticotropin-releasing

- hormone gene in NPLC cells is correlated with Z-DNA formation. *Proc Natl Acad Sci U S A*, 93, 3664-8 (1996)
97. Wolfl, S., B. Wittig, T. Dorbic & A. Rich: Identification of processes that influence negative supercoiling in the human c-myc gene. *Biochim Biophys Acta*, 1352, 213-21 (1997)
  98. Nordheim, A., M. L. Pardue, E. M. Lafer, A. Moller, B. D. Stollar & A. Rich: Antibodies to left-handed Z-DNA bind to interband regions of Drosophila polytene chromosomes. *Nature*, 294, 417-22 (1981)
  99. Lancillotti, F., M. C. Lopez, P. Arias & C. Alonso: Z-DNA in transcriptionally active chromosomes. *Proc Natl Acad Sci U S A*, 84, 1560-4 (1987)
  100. Lipps, H. J., A. Nordheim, E. M. Lafer, D. Ammermann, B. D. Stollar & A. Rich: Antibodies against Z DNA react with the macronucleus but not the micronucleus of the hypotrichous ciliate stylonychia mytilus. *Cell*, 32, 435-41 (1983)
  101. Cerna, A., A. Cuadrado, N. Jouve, S. M. Diaz de la Espina & C. De la Torre: Z-DNA, a new *in situ* marker for transcription. *Eur J Histochem*, 48, 49-56 (2004)
  102. Wittig, B., T. Dorbic & A. Rich: Transcription is associated with Z-DNA formation in metabolically active permeabilized mammalian cell nuclei. *Proc Natl Acad Sci U S A*, 88, 2259-63 (1991)
  103. Wittig, B., S. Wolfl, T. Dorbic, W. Vahrson & A. Rich: Transcription of human c-myc in permeabilized nuclei is associated with formation of Z-DNA in three discrete regions of the gene. *Embo J*, 11, 4653-63 (1992)
  104. Rothenburg, S., F. Koch-Nolte, A. Rich & F. Haag: A polymorphic dinucleotide repeat in the rat nucleolin gene forms Z-DNA and inhibits promoter activity. *Proc Natl Acad Sci U S A*, 98, 8985-90 (2001)
  105. Santoro, C., F. Costanzo & G. Ciliberto: Inhibition of eukaryotic tRNA transcription by potential Z-DNA sequences. *Embo J*, 3, 1553-9 (1984)
  106. Ausio, J., G. Zhou & K. van Holde: A reexamination of the reported B----Z DNA transition in nucleosomes reconstituted with poly (dG-m5dC).poly (dG-m5dC). *Biochemistry*, 26, 5595-9 (1987)
  107. Garner, M. M. & G. Felsenfeld: Effect of Z-DNA on nucleosome placement. *J Mol Biol*, 196, 581-90 (1987)
  108. Casasnovas, J. M. & F. Azorin: Supercoiled induced transition to the Z-DNA conformation affects the ability of a d (CG/GC)12 sequence to be organized into nucleosome-cores. *Nucleic Acids Res*, 15, 8899-918 (1987)
  109. Liu, H., N. Mulholland, H. Fu & K. Zhao: Cooperative activity of BRG1 and Z-DNA formation in chromatin remodeling. *Mol Cell Biol*, 26, 2550-9 (2006)
  110. Wong, B., S. Chen, J. A. Kwon & A. Rich: Characterization of Z-DNA as a nucleosome-boundary element in yeast *Saccharomyces cerevisiae*. *Proc Natl Acad Sci U S A* (2007)
  111. Drew, H. R., J. R. Weeks & A. A. Travers: Negative supercoiling induces spontaneous unwinding of a bacterial promoter. *Embo J*, 4, 1025-32 (1985)
  112. Wang, J. C. & A. S. Lynch: Transcription and DNA supercoiling. *Curr Opin Genet Dev*, 3, 764-8 (1993)
  113. Mizutani, M., T. Ohta, H. Watanabe, H. Handa & S. Hirose: Negative supercoiling of DNA facilitates an interaction between transcription factor IID and the fibroin gene promoter. *Proc Natl Acad Sci U S A*, 88, 718-22 (1991)
  114. Galan, J. E. & R. Curtiss, 3rd: Expression of *Salmonella typhimurium* genes required for invasion is regulated by changes in DNA supercoiling. *Infect Immun*, 58, 1879-85 (1990)
  115. Dorman, C. J., G. C. Barr, N. N. Bhriain & C. F. Higgins: DNA supercoiling and the anaerobic and growth phase regulation of tonB gene expression. *J Bacteriol*, 170, 2816-26 (1988)
  116. O'Byrne, C. P., N. Ni Bhriain & C. J. Dorman: The DNA supercoiling-sensitive expression of the *Salmonella typhimurium* his operon requires the his attenuator and is modulated by anaerobiosis and by osmolarity. *Mol Microbiol*, 6, 2467-76 (1992)
  117. Aboul-ela, F., R. P. Bowater & D. M. Lilley: Competing B-Z and helix-coil conformational transitions in supercoiled plasmid DNA. *J Biol Chem*, 267, 1776-85 (1992)
  118. Sheridan, S. D., M. L. Opel & G. W. Hatfield: Activation and repression of transcription initiation by a distant DNA structural transition. *Mol Microbiol*, 40, 684-90 (2001)
  119. Sheridan, S. D., C. J. Benham & G. W. Hatfield: Inhibition of DNA supercoiling-dependent transcriptional activation by a distant B-DNA to Z-DNA transition. *J Biol Chem*, 274, 8169-74 (1999)
  120. Liu, R., H. Liu, X. Chen, M. Kirby, P. O. Brown & K. Zhao: Regulation of CSF1 promoter by the SWI/SNF-like BAF complex. *Cell*, 106, 309-18 (2001)
  121. Peck, L. J. & J. C. Wang: Transcriptional block caused by a negative supercoiling induced structural change in an alternating CG sequence. *Cell*, 40, 129-37 (1985)
  122. de Mercoyrol, L., Y. Corda, C. Job & D. Job: Accuracy of wheat-germ RNA polymerase II. General enzymatic properties and effect of template conformational transition from right-handed B-DNA to left-handed Z-DNA. *Eur J Biochem*, 206, 49-58 (1992)
  123. Rothenburg, S., F. Koch-Nolte & F. Haag: DNA methylation and Z-DNA formation as mediators of quantitative differences in the expression of alleles. *Immunol Rev*, 184, 286-98 (2001)
  124. Wang, G. & K. M. Vasquez: Non-B DNA structure-induced genetic instability. *Mutat Res* (2006)
  125. Wells, R. D., R. Dere, M. L. Hebert, M. Napierala & L. S. Son: Advances in mechanisms of genetic instability related to hereditary neurological diseases. *Nucleic Acids Res*, 33, 3785-98 (2005)
  126. Bacolla, A., M. Wojciechowska, B. Kosmider, J. E. Larson & R. D. Wells: The involvement of non-B DNA structures in gross chromosomal rearrangements. *DNA Repair (Amst)* (2006)
  127. Wells, R. D.: Molecular basis of genetic instability of triplet repeats. *J Biol Chem*, 271, 2875-8 (1996)
  128. Bowater, R. P. & R. D. Wells: The intrinsically unstable life of DNA triplet repeats associated with human hereditary disorders. *Prog Nucleic Acid Res Mol Biol*, 66, 159-202 (2001)
  129. Popescu, N. C.: Genetic alterations in cancer as a result of breakage at fragile sites. *Cancer Lett*, 192, 1-17 (2003)

130. Zhang, Y. & J. D. Rowley: Chromatin structural elements and chromosomal translocations in leukemia. *DNA Repair (Amst)*, 5, 1282-97 (2006)
131. Kas, E. & U. K. Laemmli: *In vivo* topoisomerase II cleavage of the Drosophila histone and satellite III repeats: DNA sequence and structural characteristics. *Embo J*, 11, 705-16 (1992)
132. Udvardy, A. & P. Schedl: Chromatin structure, not DNA sequence specificity, is the primary determinant of topoisomerase II sites of action *in vivo*. *Mol Cell Biol*, 11, 4973-84 (1991)
133. Borde, V. & M. Duguet: The mapping of DNA topoisomerase sites *in vivo*: a tool to enlight the functions of topoisomerases. *Biochimie*, 80, 223-33 (1998)
134. Sabourin, M., J. L. Nitiss, K. C. Nitiss, K. Tatebayashi, H. Ikeda & N. Osheroff: Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks. *Nucleic Acids Res*, 31, 4373-84 (2003)
135. Howard, M. T. & J. D. Griffith: A cluster of strong topoisomerase II cleavage sites is located near an integrated human immunodeficiency virus. *J Mol Biol*, 232, 1060-8 (1993)
136. Glikin, G. C., T. M. Jovin & D. J. Arndt-Jovin: Interactions of Drosophila DNA topoisomerase II with left-handed Z-DNA in supercoiled minicircles. *Nucleic Acids Res*, 19, 7139-44 (1991)
137. Klysik, J., S. M. Stirdivant & R. D. Wells: Left-handed DNA. Cloning, characterization, and instability of inserts containing different lengths of (dC-dG) in Escherichia coli. *J Biol Chem*, 257, 10152-8 (1982)
138. Klysik, J., S. M. Stirdivant, J. E. Larson, P. A. Hart & R. D. Wells: Left-handed DNA in restriction fragments and a recombinant plasmid. *Nature*, 290, 672-7 (1981)
139. Freund, A. M., M. Bichara & R. P. Fuchs: Z-DNA-forming sequences are spontaneous deletion hot spots. *Proc Natl Acad Sci U S A*, 86, 7465-9 (1989)
140. Murphy, K. E. & J. R. Stringer: RecA independent recombination of poly[d (GT)-d (CA)] in pBR322. *Nucleic Acids Res*, 14, 7325-40 (1986)
141. Blaho, J. A. & R. D. Wells: Left-handed Z-DNA and genetic recombination. *Prog Nucleic Acid Res Mol Biol*, 37, 107-26 (1989)
142. Wahls, W. P., L. J. Wallace & P. D. Moore: The Z-DNA motif d (TG)<sub>30</sub> promotes reception of information during gene conversion events while stimulating homologous recombination in human cells in culture. *Mol Cell Biol*, 10, 785-93 (1990)
143. Treco, D. & N. Arnheim: The evolutionarily conserved repetitive sequence d (TG.AC)<sub>n</sub> promotes reciprocal exchange and generates unusual recombinant tetrads during yeast meiosis. *Mol Cell Biol*, 6, 3934-47 (1986)
144. Kobori, J. A., E. Strauss, K. Minard & L. Hood: Molecular analysis of the hotspot of recombination in the murine major histocompatibility complex. *Science*, 234, 173-9 (1986)
145. Wahls, W. P.: Meiotic recombination hotspots: shaping the genome and insights into hypervariable minisatellite DNA change. *Curr Top Dev Biol*, 37, 37-75 (1998)
146. Kim, J. I., J. Heuser & M. M. Cox: Enhanced recA protein binding to Z DNA represents a kinetic perturbation of a general duplex DNA binding pathway. *J Biol Chem*, 264, 21848-56 (1989)
147. Krishna, P., A. R. Morgan & J. H. van de Sande: Interaction of recA protein with left-handed Z-DNA. *Biochem J*, 275 (Pt 3), 711-9 (1991)
148. Moore, S. P., A. Rich & R. Fishel: The human recombination strand exchange process. *Genome*, 31, 45-52 (1989)
149. Kmiec, E. B. & W. K. Holloman: Homologous pairing of DNA molecules by Ustilago rec1 protein is promoted by sequences of Z-DNA. *Cell*, 44, 545-54 (1986)
150. Weinreb, A., D. A. Collier, B. K. Birshtein & R. D. Wells: Left-handed Z-DNA and intramolecular triplex formation at the site of an unequal sister chromatid exchange. *J Biol Chem*, 265, 1352-9 (1990)
151. Ngan, B. Y., J. Nourse & M. L. Cleary: Detection of chromosomal translocation t (14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. *Blood*, 73, 1759-62 (1989)
152. Emanuel, B. S., P. C. Nowell, C. McKeon, C. M. Croce & M. A. Israel: Translocation breakpoint mapping: molecular and cytogenetic studies of chromosome 22. *Cancer Genet Cytogenet*, 19, 81-92 (1986)
153. Spitzner, J. R., I. K. Chung & M. T. Muller: Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats. *Nucleic Acids Res*, 18, 1-11 (1990)
154. Zimmerman, S. B.: The three-dimensional structure of DNA. *Annu Rev Biochem*, 51, 395-427 (1982)
155. Luokkamaki, M., K. Servomaa & T. Rytaomaa: Onset of chromatin fragmentation in chloroma cell apoptosis is highly sensitive to UV and begins at non-B DNA conformation. *Int J Radiat Biol*, 63, 207-13 (1993)
156. Tartier, L., V. Michalik, M. Spothem-Maurizot, A. R. Rahmouni, R. Sabattier & M. Charlier: Radiolytic signature of Z-DNA. *Nucleic Acids Res*, 22, 5565-70 (1994)
157. Rodolfo, C., A. Lanza, S. Tornaletti, G. Fronza & A. M. Pedrini: The ultimate carcinogen of 4-nitroquinoline 1-oxide does not react with Z-DNA and hyperreacts with B-Z junctions. *Nucleic Acids Res*, 22, 314-20 (1994)
158. Tang, N., J. G. Muller, C. J. Burrows & S. E. Rokita: Nickel and cobalt reagents promote selective oxidation of Z-DNA. *Biochemistry*, 38, 16648-54 (1999)
159. Lagravere, C., B. Malfoy, M. Leng & J. Laval: Ring-opened alkylated guanine is not repaired in Z-DNA. *Nature*, 310, 798-800 (1984)
160. Boiteux, S., R. Costa de Oliveira & J. Laval: The Escherichia coli O6-methylguanine-DNA methyltransferase does not repair promutagenic O6-methylguanine residues when present in Z-DNA. *J Biol Chem*, 260, 8711-5 (1985)
161. Preisler, R. S.: The B-DNA to Z-DNA transition in alkali and tetraalkylammonium salts correlated with cation effects on solvent structure. *Biochem Biophys Res Commun*, 148, 609-16 (1987)
162. Gao, Y. G., M. Sriram & A. H. Wang: Crystallographic studies of metal ion-DNA interactions: different binding modes of cobalt (II), copper (II) and

- barium (II) to N7 of guanines in Z-DNA and a drug-DNA complex. *Nucleic Acids Res*, 21, 4093-101 (1993)
163. Gueron, M., J. Demaret & M. Filoche: A unified theory of the B-Z transition of DNA in high and low concentrations of multivalent ions. *Biophys J*, 78, 1070-83 (2000)
164. Latha, K. S., S. Anitha, K. S. Rao & M. A. Viswamitra: Molecular understanding of aluminum-induced topological changes in (CCG)<sub>12</sub> triplet repeats: relevance to neurological disorders. *Biochim Biophys Acta*, 1588, 56-64 (2002)
165. Spingler, B.: Anions or cations: who is in charge of inhibiting the nickel (II) promoted B- to Z-DNA transition? *Inorg Chem*, 44, 831-3 (2005)
166. Qu, X., J. O. Trent, I. Fokt, W. Priebe & J. B. Chaires: Allosteric, chiral-selective drug binding to DNA. *Proc Natl Acad Sci U S A*, 97, 12032-7 (2000)
167. Thomas, T. J. & R. P. Messner: Beneficial effects of a polyamine biosynthesis inhibitor on lupus in MRL-lpr/lpr mice. *Clin Exp Immunol*, 78, 239-44 (1989)
168. Kim, Y. G., K. M. Thai, J. Song, K. K. Kim & H. J. Park: Identification of Novel Ligands for the Z-DNA Binding Protein by Structure-Based Virtual Screening. *Chem Pharm Bull (Tokyo)*, 55, 340-2 (2007)

**Abbreviations:** ADAR1: Double-stranded RNA adenosine deaminase 1; IFN: interferon; VV: Vaccinia virus; DSBs: double-strand breaks; ALL: acute lymphoblastic leukemia; NRAMP1: natural resistance associated macrophage protein 1; CSF1: colony-stimulating factor 1; RNAP: RNA polymerase; HIV: Human Immunodeficiency Virus

**Key Words:** DNA structure, Z-DNA, Transcription, Recombination, Genetic instability, Translocation, Review

**Send correspondence to:** Karen M. Vasquez, Ph.D.  
University of Texas M.D. Anderson Cancer Center,  
Department of Carcinogenesis, 1808 Park Road 1-C, P.O.  
Box 389, Smithville, TX 78957, Tel: 512-237-9324, Fax:  
512-237-2475, E-Mail: kvasquez@mdanderson.org

<http://www.bioscience.org/current/vol12.htm>